BCC is new territory for cancer immunotherapies however, and Libtayo is the first drug in the PD-1/PD-L1 inhibitor class to get go-ahead in this common form of skin cancer. It's been cleared for ...

Sanofi and Regeneron plan to file their cancer immunotherapy Libtayo (cemiplimab) in a new indication following supportive findings from a phase 2 trial in a hard to treat group of skin cancer ...

They pointed to "dramatically improved" survival outcomes with immunotherapy, and objective response rates of 44% to 60% with ...

solnerstotug and Libtayo (cemiplimab) and remains on treatment at 42 or more weeks after previously receiving PD-L1 therapy for 15 months in the adjuvant setting before progressing. Complete response: ...

Libtayo reached $367M in Q4 global sales, up 50% year-over-year, supported by gains in lung cancer and non-melanoma skin ...